Use of PEG-asparaginase in a case of Hepatosplenic γδ T-cell lymphoma with long-term remission after stem cell transplantation

Kai Sun, Cesar Gentille Sanchez, Sai Ravi Pingali, Swaminathan Iyer

Research output: Contribution to journalArticlepeer-review

1 Scopus citations

Abstract

Hepatosplenic γδ T-cell lymphoma (HSTCL) is a rare aggressive peripheral T-cell lymphoma. Prognosis is usually poor with a median survival between 8 and 16 months after traditional chemotherapy. Stem cell transplantation (SCT) is promising and with a more intense induction regimen, has yielded positive results. We report the use of pegylated-asparaginase (PEG-asparaginase) along with a conventional anthracycline-containing regimen in a 51-year-old male who was diagnosed with HSTCL, achieved a complete remission, and subsequently underwent peripheral blood SCT and remained in remission at the time of this case report.

Original languageEnglish (US)
Article number872
Journalecancermedicalscience
Volume12
DOIs
StatePublished - Sep 20 2018

Keywords

  • Hepatosplenic γδ T-cell lymphoma
  • Pegylated-asparaginase
  • Stem cell transplant

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'Use of PEG-asparaginase in a case of Hepatosplenic γδ T-cell lymphoma with long-term remission after stem cell transplantation'. Together they form a unique fingerprint.

Cite this